Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for...

Related Keywords

Brazil ,Mexico ,Philippines ,United States ,Hong Kong ,Argentina ,China ,South Africa ,American ,Chris Fang ,Brii Bio ,David Margolis ,Erics Daar ,Darcie Robinson ,Brii Biosciences Limited Bio ,Clinical Trials Group ,Drug Administration ,Lundquist Institute At ,China National Medical Products Administration ,Brii Biosciences ,Department Of Health ,Brii Biosciences Limited ,Weill Cornell Medicine ,Lundquist Institute ,Vice President ,Infectious Diseases Therapy ,Emergency Use Authorization ,New Drug ,Trials Group ,Biosciences Limited ,